Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.2 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board, at its meeting on February 13, 2026, approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Standalone revenue for the quarter appears to have grown roughly 18–19% year-on-year, with nine-month revenue rising around 16% to approximately ₹850 lakhs (vs ~₹731 lakhs in 9M FY25). However, standalone profit after tax fell sharply in Q3 — from about ₹78.45 lakhs in Q3 FY25 to roughly ₹56.56 lakhs in Q3 FY26, a decline of around 28% — even as 9M PAT softened modestly to ~₹167 lakhs. The consolidated results, which include subsidiaries Polo Queen Capital, Polo Queen Pharma Trade Industry, and Polo Queen Solutions, show a similar pattern. Auditor N.K. Jalan & Co. issued an unmodified limited review report on both sets of results, with no qualifications or emphasis-of-matter issues.
Mixed picture for shareholders — top-line momentum is intact but bottom-line is under pressure in Q3, with a sharp PAT drop despite revenue growth, suggesting margin compression. The clean auditor report removes any immediate governance red flags, but the profitability weakness will likely cap near-term investor enthusiasm.